CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll
A majority of cystic fibrosis patients who took part in an Instagram poll by Bionews Services said they would be interested in moving from current treatments to Trikafta (elexacaftor, tezacaftor, and ivacaftor), the newly approved and “next-generation” combination therapy by Vertex that is expected to treat 90% of all…